← Back to Search

Cancer Vaccine

HPV Education for HPV

Phase 4
Recruiting
Led By Gerardo Colon-Otero, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For female patients, no history of positive HPV testing or abnormal Papanicolaou (Pap) smears
No history of HPV vaccination
Must not have
Individuals who had previously received the HPV vaccine
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial looks at whether an educational program about HPV can increase the rates of HPV vaccination among low income uninsured adults, which may prevent HPV-related cancers.

Who is the study for?
This trial is for adults who have never had an HPV vaccine, no allergies to its contents, and women without a history of positive HPV tests or abnormal Pap smears. Participants must understand English, be patients at the VIM clinic, and willing to join the study. Those who've already received the HPV vaccine cannot participate.
What is being tested?
The trial is testing whether an educational program can increase acceptance and completion of free HPV vaccinations among underserved adults. It aims to boost vaccination rates in this group which may help prevent HPV-related cancers.
What are the potential side effects?
Since this trial involves an educational intervention rather than a medical treatment, there are no direct side effects from medications or vaccines as part of the study itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have never had a positive HPV test or abnormal Pap smear.
Select...
I have never received the HPV vaccine.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have received the HPV vaccine.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: Prevention (HPV educational program)Experimental Treatment2 Interventions
Patients receive educational materials on HPV and are asked of their willingness to proceed with the first HPV vaccination. Patients who express interest in receiving the HPV vaccination, then receive the first dose of the HPV vaccine and the next 2 doses approximately 2 months and 6 months following the initial vaccine.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,700 Total Patients Enrolled
Mayo ClinicLead Sponsor
3,298 Previous Clinical Trials
3,958,145 Total Patients Enrolled
Gerardo Colon-Otero, M.D.Principal InvestigatorMayo Clinic
3 Previous Clinical Trials
486 Total Patients Enrolled

Media Library

HPV Vaccination (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04474821 — Phase 4
~73 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top